Short Wave Folgen

Kwasi Wrensford describes the subjects of his research as "elfin": skittish little squirrel-cousins with angular faces, pointy ears and narrow, furry tails. He studies two species in particular: the Alpine chipmunk and the Lodgepole chipmunk. As the climate warms, these two chipmunks have developed different ways of coping. The Alpine chipmunk has climbed higher, in search of cooler habitat, while the Lodgepole chipmunk continues to thrive in its historic habitat. On this episode, Kwasi explains to Emily Kwong how these squirrelly critters typify two important evolutionary strategies, and why they could shed light on what's in store for other creatures all over the globe. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

This week, the UN Biodiversity Conference (COP 15) wrapped up in Montreal, Canada. Nations from around the world came together to establish a new set of goals to help preserve the planet's biodiversity and reduce the rate of loss of natural habitats. The last time biodiversity targets were set was in 2010, at COP 10. In the 12 years since, the world collectively failed to meet any of those biodiversity benchmarks.Aaron Scott talks to Giuliana Viglione, an editor at Carbon Brief covering food, land and nature. She shares what she saw on the ground at COP 15, what the new goals for 2030 are, and why she has more hope that progress will be made this time around.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Psychedelic drugs – like LSD, salvia, ayahuasca, Ibogaine, MDMA (AKA ecstasy), or psilocybin (AKA 'magic mushrooms' or 'shrooms') – are experiencing a resurgence of interest in their potential medical benefits. At the Neuroscience 2022 meeting held by the Society of Neuroscience, the appetite for psychedelic research permeated the sessions, discussions, and even after-hours barroom talk — drawing in researchers, neuroscientists, companies, reporters, and advocates alike. "In the last couple of years there has been a lot of excitement in psychedelics. I think it started first in the popular media." says Alex Kwan, associate professor at Cornell University. "Neuroscience, actually, I think took another year or two to catch on." Today on the show, host Aaron Scott and NPR's brain correspondent Jon Hamilton chat psychedelic drugs — whether this renewed interest will represent incremental or revolutionary changes in the fields of medicine, psychology, and neuroscience.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy